A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)

  • STATUS
    Recruiting
  • End date
    Jun 30, 2023
  • participants needed
    270
  • sponsor
    Cutia Therapeutics(Wuxi)Co.,Ltd
Updated on 25 March 2022

Summary

A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

Details
Condition AGA
Treatment CU-40102 Spray
Clinical Study IdentifierNCT05135468
SponsorCutia Therapeutics(Wuxi)Co.,Ltd
Last Modified on25 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Having voluntarily signed the ICF approved by the Ethics Committee and consented to participate in this study before starting any study procedure
Being able to understand and comply with the requirements of the protocol and agreeing to participate in all study visits
Males aged 18 to 41 years (inclusive)
Being diagnosed with Type III vertex, Type IV or Type V androgenetic alopecia (AGA) according to the Hamilton-Norwood classification (see Appendix 1 for details)
Appropriate medical contraceptive methods being used to prevent the sexual partner from becoming pregnant from the time of signing ICF to 28 days after the last dose; -

Exclusion Criteria

A history of scalp skin abnormalities or scalp skin diseases at the time of screening
Patients with secondary alopecia such as those associated with malnutrition, drugs, endocrine , iron deficiency anemia, or systemic lupus erythematosus
Patients with alopecia areata, alopecia cicatrisata, or trichotillomania
Having undergone hair transplantation or extension before screening, or persistent requirement to wear a wig sheath during study treatments
Known allergy to the active ingredient of the investigational drug or any component of the excipients, or to any component of the tattoo liquid
A history of depression, anxiety, personality disorder or other mental disorders
A history of varicocele or infertility
A history of malignant tumor
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note